Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency
Current opinion in allergy and clinical immunology, 2010•journals.lww.com
In the last decade, gene therapy has been developed as a successful and safe alternative
strategy for patients affected by ADA-SCID lacking a compatible sibling donor. The
application of innovative vector technology might further improve its efficacy and safety
profile.
strategy for patients affected by ADA-SCID lacking a compatible sibling donor. The
application of innovative vector technology might further improve its efficacy and safety
profile.
Summary
In the last decade, gene therapy has been developed as a successful and safe alternative strategy for patients affected by ADA-SCID lacking a compatible sibling donor. The application of innovative vector technology might further improve its efficacy and safety profile.
Lippincott Williams & Wilkins